Two disease mechanisms operate in Lafora progressive myoclonus epilepsy (Lafora PME) to produce 3 phenotypes (epilepsy, rapid neurologic deterioration, and Lafora polyglucosan inclusion bodies). These 2 disease mechanisms are 1) an error in glycogen metabolism and 2) neurodegeneration. The question is, which comes first and which is primary and more important in disease production?
In this issue of Neurology ® , Girard et al. 1 support the concept of Lafora PME as an error in glycogen metabolism. They ask why polyglucosans accumulate in the somadendritic compartment in Lafora PME and produce epilepsy and why, by contrast, polyglucosans accumulate in axons/axon hillocks in adult polyglucosan body disease (APBD) and produce an axonopathy without epilepsy-in spite of the fact that polyglucosan of Lafora PME is identical to polyglucosan of APBD. Girard et al. hypothesize that the reason is phosphorylation. As a corollary to this hypothesis, they posit that phosphorylated polyglucosans are the primary cause of Lafora PME. Because of a deleted or dysfunctional mutated laforin, whose phosphatase or dephosphorylation function is located in its exon 1, polyglucosan in Lafora PME stays phosphorylated (figure e-1 on the Neurology ® Web site at www.neurology.org). Polyglucosan in APBD is not phosphorylated, having been formed by mutations in the glycogen branching enzyme (GBE1). Nonphosphorylated polyglucosan is free to migrate from the somadendritic compartment to the axon. In their test of this hypothesis, they used dextran, a poorly branched nonphosphorylated polyglucosan produced by fermenting bacteria as a surrogate for Lafora or APBD polyglucosan. Further, they used an animal model of Lafora PME, the epm2aϪ/Ϫ mouse. They injected either phosphorylated dextran or dextran into wild-type or Lafora mice, and showed that phosphorylated dextran only prevented polyglucosan migration from cell soma and dendrites to distal axons. 1 To understand the significance of these experiments, the 2 disease mechanisms in Lafora PME are discussed.
LAFORA PME AS A GLYCOGEN STORAGE DISEASE Laforin/dual specificity phosphatase is the gene product of EPM2A, mutated in 70% of patients with Lafora PME. Laforin normally acts as a glycogen phosphatase and corrects an error produced by glycogen synthase. The primary action of glycogen synthase is elongation of glycogen by adding glucose residues, packing 55,000 glucose molecules per glycogen, which maintains solubility. In what is probably a catalytic error, glycogen synthase also incorporates a phosphate into glycogen via the B-phosphate of its substrate UDP-glucose, at a rate of 1 phosphate per approximately 10,000 glucose residues.
2 As a phosphatase, laforin normally removes phosphate from glycogen, correcting the error of glycogen synthase and preventing formation of phosphorylated, poorly branched insoluble glycogen polymers (Lafora polyglucosan bodies).
Another function of laforin is to work with malin/E3 ubiquitin ligase, the gene product of EPM2B, the second disease-causing gene, responsible for approximately 27% of Lafora PME. Laforin and malin in concert cause proteasome-dependent degradation of PTG, a scaffold adaptor protein in exon 4 of laforin (figure e-1). Protein targeting glycogen (PTG) binds and targets glycogen and the enzymes involved in glycogen synthesis. 3 This includes bringing protein phosphatase 1 to glycogen synthase, activating this enzyme, which then synthesizes glycogen. PTG also normally brings glycogen synthase to laforin. Thus, the laforin-malin complex, by degrading PTG, ensures a blockade of neuronal glycogen synthesis under normal conditions. Consequently, there is no glycogen in neurons under normal conditions. In the presence of a mutated laforin or malin, PTG is not degraded, the enzyme machinery for glycogen synthesis is anchored to PTG, and excessive less soluble glycogen with fewer ␣-1,6 branchpoints is formed and deposited in neurons and cell death results. 3, 4 To disable the function of glycogen synthase, Turnbull et al. 5 genetically removed PTG in epm2aϪ/Ϫ mice. Polyglucosan inclusions were dramatically reduced, and mice were rescued from neurodegeneration and myoclonic epilepsy, compelling evidence that phosphorylated glycogen is a, if not the, primary cause of Lafora PME.
LAFORA PME AS A NEURODEGENERATIVE DISEASE Elegant as the Girard et al. 1 experiments are, the presence of neurodegeneration in Lafora PME cannot be denied. As early as 11 days and certainly at 2 months of age, homozygous null mutants (epm2aϪ/Ϫ) develop widespread degeneration of neurons 6 and neurofibrillary tangles (hyperphosphorylated Tau protein [Ser(396) and Ser(202)]). 7 Most of these occur in the absence of Lafora bodies. When Lafora bodies form in neuronal and non-neural tissues they are positive for ubiquitin and advanced glycation end-products only in neurons. This means that protein misfolding contributes to formation of Lafora inclusions in neurons and provides evidence that Lafora disease is also a neurodegenerative disorder. Laforin and malin both localize in endoplasmic reticulum and form centrosomal aggregates when treated with proteasomal inhibitors in both neuronal and non-neuronal cells. The centrosomal accumulation of malin, with help from laforin, enhances ubiquitination of its substrates and facilitates efficient degradation by proteasome. Defects in malin or laforin thus lead to increased misfolded proteins, impairing degradation and clearance, and contribute to cell death. 8 
AUTOPHAGY PRECEDES, CONNECTS POLY-GLUCOSAN STORAGE, PROTEIN CLEARANCE, AND NEURODEGENERATION IN LAFORA PME
How then do polyglucosan Lafora bodies connect with neurodegeneration? Autophagy is a catabolic process involved in degradation of cell components through lysosomes. In epm2aϪ/Ϫ mice, loss of laforin inhibits autophagosome formation, suggesting laforin plays a role in autophagosome biogenesis. 9 Polyglucosan inclusion bodies are substrates of autophagy and mutated laforin affects their sequestration into autophagosomes. Loss of laforin impairs autophagy in cell lines from human patients, in embryonic fibroblasts and tissues from epm2aϪ/Ϫ mice and epm2bϪ/Ϫ mice. Impaired autophagy precedes polyglucosan formation. Interestingly, laforin regulates autophagy via the mammalian target of rapamycin kinasedependent pathway. 10 Clinicians should familiarize themselves with PTG, the scaffold adaptor protein of laforin that binds and targets glycogen and enzymes involved in glycogen synthesis, the ubiquitin/proteasome system, and rapamycin regulation of autophagy, as all are now targets for curative drug development in Lafora PME.
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